CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
Polypodium Leucotomosdrug
Likely dose
Polypodium Leucotomos 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02904798
NCT02904798N/ACompleted
CompareCT.gov

The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos

Henry Ford Health System·interventional·Posted Sep 19, 2016·Updated Mar 3, 2022

In Brief

A clinical study evaluating Polypodium Leucotomos for Photodermatoses. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Polypodium Leucotomos Extract (PLE) is a tropical fern that has antioxidative, photoprotective, chemoprotective, anti-inflammatory, and immunomodulatory properties. The antioxidative effects of PL include inhibition and scavenging of free radicals, lipid peroxidation and reactive oxygen species (ROS) such hydrogen peroxide, superoxide anion, hydroxyl radical and singlet oxygen. Visible light (400-700 nm) causes pigmentation in melanocompetent individuals and induces DNA damage in the human skin through ROS production. The goal of this study is to determine whether the administration of oral PLE has an effect on the development of visible light induced pigmentation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhotodermatoses
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 19, 2016
Enrollment StartJul 1, 2015
Primary CompletionFeb 14, 2017
Study CompletionApr 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.8 years ago

Interventions

Polypodium Leucotomosdrug

\- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light